Management of nodal diffuse large B-cell lymphomas

Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Giovanni Barosi, Angelo Carella, Mario Lazzarino, Monia Marchetti, Maurizio Martelli, Alessandro Rambaldi, Corrado Tarella, Umberto Vitolo, Pier Luigi Zinzani, Sante Tura

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of nodal diffuse large B-cell non Hodgkin lymphomas (DLBCL). Key questions clinically relevant to the management of patients with nodal DLBCL were formulated by an Advisory Committee (AC) and approved by an Expert Panel (EP) composed of eight senior hematologists. After a comprehensive and systematic literature review, the EP formulated therapy recommendations and graded them according to the supporting evidence. An explicit approach to consensus methodologies was used for evidence interpretation and for producing recommendations in the absence of strong evidence. The EP formulated recommendations on which first-line therapy to choose in patients with nodal DLBCL. Patients of all ages, with stage I-II disease and no adverse prognostic factors should receive abbreviated chemotherapy with an anthracycline-containing regimen plus involved field radiotherapy (35-40 Gy). Patients with stage I-II disease and at least one adverse prognostic factor, or with stage III-IV disease, should receive frontline chemoimmunotherapy with CHOP, CHOP-like or third-generation chemotherapy plus rituximab. Recommendations on stem cell transplantation and on which therapy to adopt for refractory or relapsed patients were also formulated.

Original languageEnglish
Pages (from-to)96-103
Number of pages8
JournalHaematologica
Volume91
Issue number1
Publication statusPublished - Jan 2006

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Hematology
Bone Marrow Transplantation
Practice Guidelines
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Drug Therapy
Anthracyclines
Stem Cell Transplantation
Advisory Committees
Therapeutics
Radiotherapy

Keywords

  • Chemotherapy
  • Clinical practice guidelines
  • Non-Hodgkins lymphoma
  • Rituximab
  • Systematic review

ASJC Scopus subject areas

  • Hematology

Cite this

Management of nodal diffuse large B-cell lymphomas : Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. / Barosi, Giovanni; Carella, Angelo; Lazzarino, Mario; Marchetti, Monia; Martelli, Maurizio; Rambaldi, Alessandro; Tarella, Corrado; Vitolo, Umberto; Zinzani, Pier Luigi; Tura, Sante.

In: Haematologica, Vol. 91, No. 1, 01.2006, p. 96-103.

Research output: Contribution to journalArticle

Barosi, Giovanni ; Carella, Angelo ; Lazzarino, Mario ; Marchetti, Monia ; Martelli, Maurizio ; Rambaldi, Alessandro ; Tarella, Corrado ; Vitolo, Umberto ; Zinzani, Pier Luigi ; Tura, Sante. / Management of nodal diffuse large B-cell lymphomas : Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. In: Haematologica. 2006 ; Vol. 91, No. 1. pp. 96-103.
@article{c738197f9959406991f3ddd476bc4eaa,
title = "Management of nodal diffuse large B-cell lymphomas: Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation",
abstract = "The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of nodal diffuse large B-cell non Hodgkin lymphomas (DLBCL). Key questions clinically relevant to the management of patients with nodal DLBCL were formulated by an Advisory Committee (AC) and approved by an Expert Panel (EP) composed of eight senior hematologists. After a comprehensive and systematic literature review, the EP formulated therapy recommendations and graded them according to the supporting evidence. An explicit approach to consensus methodologies was used for evidence interpretation and for producing recommendations in the absence of strong evidence. The EP formulated recommendations on which first-line therapy to choose in patients with nodal DLBCL. Patients of all ages, with stage I-II disease and no adverse prognostic factors should receive abbreviated chemotherapy with an anthracycline-containing regimen plus involved field radiotherapy (35-40 Gy). Patients with stage I-II disease and at least one adverse prognostic factor, or with stage III-IV disease, should receive frontline chemoimmunotherapy with CHOP, CHOP-like or third-generation chemotherapy plus rituximab. Recommendations on stem cell transplantation and on which therapy to adopt for refractory or relapsed patients were also formulated.",
keywords = "Chemotherapy, Clinical practice guidelines, Non-Hodgkins lymphoma, Rituximab, Systematic review",
author = "Giovanni Barosi and Angelo Carella and Mario Lazzarino and Monia Marchetti and Maurizio Martelli and Alessandro Rambaldi and Corrado Tarella and Umberto Vitolo and Zinzani, {Pier Luigi} and Sante Tura",
year = "2006",
month = "1",
language = "English",
volume = "91",
pages = "96--103",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Management of nodal diffuse large B-cell lymphomas

T2 - Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

AU - Barosi, Giovanni

AU - Carella, Angelo

AU - Lazzarino, Mario

AU - Marchetti, Monia

AU - Martelli, Maurizio

AU - Rambaldi, Alessandro

AU - Tarella, Corrado

AU - Vitolo, Umberto

AU - Zinzani, Pier Luigi

AU - Tura, Sante

PY - 2006/1

Y1 - 2006/1

N2 - The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of nodal diffuse large B-cell non Hodgkin lymphomas (DLBCL). Key questions clinically relevant to the management of patients with nodal DLBCL were formulated by an Advisory Committee (AC) and approved by an Expert Panel (EP) composed of eight senior hematologists. After a comprehensive and systematic literature review, the EP formulated therapy recommendations and graded them according to the supporting evidence. An explicit approach to consensus methodologies was used for evidence interpretation and for producing recommendations in the absence of strong evidence. The EP formulated recommendations on which first-line therapy to choose in patients with nodal DLBCL. Patients of all ages, with stage I-II disease and no adverse prognostic factors should receive abbreviated chemotherapy with an anthracycline-containing regimen plus involved field radiotherapy (35-40 Gy). Patients with stage I-II disease and at least one adverse prognostic factor, or with stage III-IV disease, should receive frontline chemoimmunotherapy with CHOP, CHOP-like or third-generation chemotherapy plus rituximab. Recommendations on stem cell transplantation and on which therapy to adopt for refractory or relapsed patients were also formulated.

AB - The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of nodal diffuse large B-cell non Hodgkin lymphomas (DLBCL). Key questions clinically relevant to the management of patients with nodal DLBCL were formulated by an Advisory Committee (AC) and approved by an Expert Panel (EP) composed of eight senior hematologists. After a comprehensive and systematic literature review, the EP formulated therapy recommendations and graded them according to the supporting evidence. An explicit approach to consensus methodologies was used for evidence interpretation and for producing recommendations in the absence of strong evidence. The EP formulated recommendations on which first-line therapy to choose in patients with nodal DLBCL. Patients of all ages, with stage I-II disease and no adverse prognostic factors should receive abbreviated chemotherapy with an anthracycline-containing regimen plus involved field radiotherapy (35-40 Gy). Patients with stage I-II disease and at least one adverse prognostic factor, or with stage III-IV disease, should receive frontline chemoimmunotherapy with CHOP, CHOP-like or third-generation chemotherapy plus rituximab. Recommendations on stem cell transplantation and on which therapy to adopt for refractory or relapsed patients were also formulated.

KW - Chemotherapy

KW - Clinical practice guidelines

KW - Non-Hodgkins lymphoma

KW - Rituximab

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=32544438620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544438620&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 96

EP - 103

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -